| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Advertising > A Different View on Pricing - From a South African Perspective |
|
Advice You - A Different View on Pricing - From a South African Perspective
A business researching and developing a new product normally designs it first and the estimat According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product es the cost to determine the final price. If the cost - and the resulting price - are too hig ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in , the product will go back to the drawing board for more revisions, delaying the introduction lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. of the new product. The Japanese approach is to start with a target cost based on the price here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe hat consumers are most likely to accept; then the designers and manufacturers engineer the pr d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro oduct to meet that target. The Japanese system focuses on pinning down the key cost elements ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc f the product in the planning and design stage. This concept is central to the entire process easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi because that is the point at which virtually all subsequent costs of the product are built in nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically - from manufacturing to service. Careful planning and co-ordination in this phase means lower and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ costs and better cost control further down the manufacturing pipeline. The Japanese approac ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi relies on a team of workers from a wide array of disciplines to bring a product to market. T ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a e team researches the market to come up with the products target price. From this crucial dec dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod sion all else follows. After deducting the desired profit from the target sales price, the te cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin am of planners develops cost estimates for each element of the product. The team treats every tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen part or function as a component and assigns each one a part of the target cost. This is where t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel the battle begins. The Japanese use the word tataku, which means "to beat down," to describe ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust he battle over costs with their suppliers. The battle is an intense negotiation process betwe y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products en the company and outside suppliers to push down costs to meet the overall target cost. Init . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ally, the sum of the components' cost estimates may exceed the overall target cost, but by th elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip time the battle is over, the team is usually within striking distance of the original target tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Anti-Dumping and International Trade
|